

1 **Article type:** Original Investigation

2 **Title: Neurokinin-1 receptor antagonist tradipitant improves itch associated with mild atopic dermatitis:**  
3 **Results from EPIONE a randomized clinical trial**

4 Sarah E Welsh, PhD<sup>1</sup>, Changfu Xiao, PhD<sup>1</sup>, Michael A Mohrman<sup>1</sup>, Alyssa R Kaden<sup>1</sup>, Jennifer L Brzezynski<sup>1</sup>,  
5 Jingyuan Wang, PhD<sup>1</sup>, Sandra P Smieszek, PhD<sup>1</sup>, Bartlomiej Przychodzen, PhD<sup>1</sup>, Sonja Ständer, MD<sup>2</sup>,  
6 Christos Polymeropoulos, MD<sup>1</sup>, Gunther Birznieks<sup>1</sup>, Mihael H Polymeropoulos, MD<sup>1</sup>

7 <sup>1</sup>Vanda Pharmaceuticals Inc., 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037

8 <sup>2</sup>Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Germany

9 **Corresponding author:**

10 Sandra P. Smieszek, PhD  
11 2200 Pennsylvania NW, Suite 300-E  
12 Washington, DC 20037  
13 Email: [Sandra.Smieszek@vandapharma.com](mailto:Sandra.Smieszek@vandapharma.com)

14  
15 **Funding source:** Vanda Pharmaceuticals Inc.

16  
17 **Conflicts of Interest:** SEW is a former employee of Vanda and a stockholder. CX is an employee of Vanda  
18 and a stockholder. MAM is an employee of Vanda and a stockholder. ARK is an employee of Vanda. JLB is  
19 an employee of Vanda and a stockholder. JW is an employee of Vanda and a stockholder. SPS is an  
20 employee of Vanda and a stockholder. BP is an employee of Vanda and a stockholder. SS is an  
21 investigator for Dermasence, Galderma, Kiniksa Pharmaceuticals, Menlo Therapeutics, Trevi  
22 Therapeutics, Novartis, Sanofi, and Vanda Pharmaceuticals Inc.; and is a consultant and/or member of  
23 the advisory board for Almirall, Bayer, Beiersdorf, Bellus Health, Bionorica, Cara Therapeutics, Celgene,  
24 Clexio Biosciences, DS Biopharma, Galderma, Menlo Therapeutics, Novartis, Perrigo, and Trevi  
25 Therapeutics. CP is an employee of Vanda and a stockholder. GB is an employee of Vanda and a  
26 stockholder. MHP is Chief Executive Officer of Vanda.

27  
28 **IRB approval status:** Reviewed and approved by Advarra IRB; Pro00025510

29  
30 **Manuscript word count:** 2608

31  
32 **Data Sharing Statement:** Vanda shares data related to this trial in peer-reviewed journals, medical  
33 conferences, and ClinicalTrials.gov. Individual patient data are not publically available.

34 **Data available:** No

35

36 This manuscript has not been published and is not under consideration for publication elsewhere.

## 37 **Abbreviations**

AD	Atopic Dermatitis
AE	Adverse Event
BMI	Body Mass Index
BSA	Body Surface Area
EASI	Eczema Area and Severity Index
IGA	Investigator Global Assessment
ITT	Intent-to-Treat
LS Mean	Least Squared Mean
MMRM	Mixed Model Repeated Measures
NGF	Nerve Growth Factor
NK-1	Neurokinin-1
NRS	Numerical Rating Scale
POEM	Patient-Oriented Eczema Measure
SAE	Serious Adverse Event
SCORAD	SCORing Atopic Dermatitis
SP	Substance P
TEAE	Treatment Emergent Adverse Event
VAS	Visual Analogue Scale
vIGA-AD	Validated Investigator Global Assessment for Atopic Dermatitis
WI-NRS	Worst Itch Numerical Rating Scale

38

39 **Key Points**

40 **Question:** Is tradipitant, a selective neurokinin-1 receptor antagonist, efficacious and safe for improving  
41 worst itch in patients with mild to severe atopic dermatitis (AD)?

42 **Findings:** In 375 mild to severe AD patients, tradipitant did not significantly improve worst itch.

43 However, in a subgroup of 79 AD patients with mild lesion severity at baseline, tradipitant significantly  
44 improved worst itch and sleep during 8 weeks of treatment.

45 **Meaning:** These data support the role of neurokinin-1 antagonism and substance P signaling in chronic  
46 pruritus related to mild AD, and further suggest tradipitant may represent a new oral systemic option  
47 for mild AD patients based on the well-tolerated safety profile and improvement in itch and sleep.

48 **Abstract**

49 **Importance:** Safe oral systemic treatments are needed to treat itch associated with atopic dermatitis  
50 (AD).

51 **Objective:** To examine the efficacy and safety of tradipitant, a neurokinin-1 receptor antagonist, in adults with mild  
52 to severe AD.

53 **Design, Setting, and Participants:** EPIONE was a phase 3, randomized, placebo-controlled, double-blind  
54 clinical trial conducted from July 09, 2018 to December 27, 2019 at 74 US centers. Patients were adults  
55 18 years or older with worst itch rated  $\geq 7$  on the Worst Itch Numerical Rating Scale (WI-NRS) and  $\geq 1\%$   
56 body surface area of AD involvement at screening.

57 **Interventions:** Patients were randomly assigned (1:1) to twice-daily oral placebo or tradipitant (85 mg)  
58 for 8 weeks.

59 **Main Outcomes and Measures:** The primary endpoint was mean improvement in WI-NRS (baseline to  
60 Week 8). Secondary endpoints included disease severity improvement measured by SCORing Atopic  
61 Dermatitis (SCORAD) index, the Eczema Area and Severity Index (EASI), and validated Investigator Global  
62 Assessment for Atopic Dermatitis (vIGA-AD<sup>TM</sup>).

63 **Results:** 341 patients (mean [SD]: age, 41.8 [15.0] years; sex, 243 [64.8%] female) were randomly assigned to  
64 placebo (n = 187) or tradipitant (n = 188). EPIONE did not meet its primary endpoint of reduction in pruritus (LS  
65 Mean difference (95% CI), -0.2 (-0.8 to 0.4),  $P = 0.567$ ). However, robust antipruritic effect was observed in  
66 patients with mild lesion severity (rated 1 or 2 by the vIGA-AD at baseline, -1.6 (-2.9 to -0.3),  $P = 0.015$ ). This result  
67 was confirmed by daily diary (-2.09 (-3.31 to -0.87),  $P = 0.001$ ) and observed after one full day of treatment (-0.61  
68 (-1.21 to -0.01),  $P = 0.0457$ ). Treatment-emergent adverse events (TEAEs) were reported in 63 of 188 (33.5%)  
69 tradipitant patients and 43 of 187 (23.0%) placebo patients. TEAEs with  $> 2\%$  incidence and twice that of placebo  
70 included diarrhea (VLY-686 = 5 (2.7%), PBO = 1 (0.5%)), fatigue (VLY-686 = 5 (2.7%), PBO = 0 (0.0%)), and  
71 worsening of AD (VLY-686 = 4 (2.1%), PBO = 1 (0.5%)).

72 **Conclusions and Relevance:** During 8 weeks of treatment, tradipitant was well-tolerated for all study participants,  
73 but did not significantly improve worst itch in the overall study population. However, in patients with mild AD at  
74 baseline, tradipitant was observed to have a large and rapid antipruritic effect. These data support the role of  
75 neurokinin-1 antagonism and substance P signaling in chronic pruritus related to mild AD. If these findings replicate in  
76 the on-going phase 3 study, EPIONE2, tradipitant may represent a promising new oral therapy for these mild AD  
77 patients.

78 **Trial Registration:** Clinicaltrials.gov: NCT03568331, <https://clinicaltrials.gov/ct2/show/NCT03568331>

## 79 Introduction

80 Atopic dermatitis (AD) is a relapsing and remitting disease that affects 4.9% of the US population<sup>1</sup>. AD is  
81 characterized by intense pruritus that can lead to scratching and eczematous lesions that vary in extent  
82 and severity. Over 60% of AD cases are mild, characterized by slight erythema, induration, and  
83 lichenification<sup>2,3</sup>. Moderate to severe cases of AD are characterized by clearly perceptible erythema,  
84 induration, lichenification, oozing, cracking, flaking, and bleeding of the skin<sup>4</sup>. Despite the wide range of  
85 severity, the American Academy of Dermatology defines pruritus as an essential feature for all clinical  
86 diagnoses of AD, including in mild AD, where pruritus can be of high intensity<sup>5,6</sup>. Chronic pruritus,  
87 pruritus lasting more than 6 weeks, has been reported by 91% of AD patients<sup>7,8</sup>. Chronic pruritus is  
88 especially distressing, as it can disturb sleep and contribute to psychological and social morbidity<sup>9</sup>.

89 The pathophysiology of AD is driven by a combination of skin barrier dysfunction, neuroinflammation,  
90 and immune system dysregulation<sup>10,11</sup>. Normally, the outermost layer of the skin is composed of tightly  
91 compacted lipid-protein matrices, which minimizes water loss from the body and prevents pathogen  
92 and allergen entry<sup>11,12</sup>. A known loss-of-function mutation in the gene Filaggrin can lead to a disruption  
93 in the integrity of these matrices<sup>13</sup>. Scratching induced by pruritus can physically damage the skin barrier  
94 and promote further inflammation. Activated immune cells (Th2, Th17, Th22) release a variety of  
95 cytokines and chemokines, including IL-4, IL-31, and IL-13, that activate other cells such as antigen  
96 presenting cells, dendritic cells, basophils, and mast cells to release pro-inflammatory mediators, and  
97 lead to further disturbance of epidermal differentiation and barrier damage. These molecules also  
98 mediate pruritus by acting on the sensory neurons in the skin<sup>8</sup>. Activated sensory fibers in the epidermis  
99 and upper dermis signal itch and burning/stinging pain, and release neuropeptides. The neuropeptides  
100 themselves can cause vasodilation, plasma extravasation, and edema. By attraction of T-cells, the  
101 neuropeptides also promote inflammation, resulting in the so-called neuroinflammation. Inflammatory  
102 responses and genetic predisposition appear to be dependent on level of lesion severity (Smieszek et al.

103 2020, under revision)<sup>14,15</sup>. Together these factors likely combine to amplify the inflammatory response  
104 and AD presentation, and contribute to the propagation of the “itch-scratch cycle”<sup>16</sup>.

105 Currently, topical steroids, calcineurin inhibitors, and emollients are the most common treatments for  
106 AD<sup>3</sup>. Steroids target the dysregulated immune pathways, and emollients aim to address the skin barrier  
107 dysfunction<sup>17</sup>. Antihistamines are often used in combination with other therapies to mediate itch<sup>3</sup>,  
108 however as the itch associated with AD is non-histaminergic, antihistamines often have an insufficient  
109 effect on relieving pruritus<sup>8</sup>. More recently, direct immunomodulatory agents, such as crisaborole and  
110 dupilumab, have been developed for moderate to severe AD. Despite the availability of these therapies,  
111 over 40% of AD patients rate dissatisfaction with their current treatment plan and identify pruritus as a  
112 persistent feature of their disease, with the reduction of itch as the most important treatment goal<sup>18,19</sup>.

113 Therefore, novel, well-tolerated therapies are needed to treat itch.

114 Elevated substance P (SP) is found in both serum and lesional skin of patients with AD<sup>8,20,21</sup>. SP, a  
115 neuropeptide released from the activation of sensory neurons, preferentially binds to the neurokinin-1  
116 (NK-1) receptor and is a known itch mediator<sup>8,22</sup>. The NK-1 receptor is found on mast cells,  
117 keratinocytes, and central and peripheral nerve endings<sup>23</sup>. Activation of the NK-1 receptor by SP leads to  
118 intracellular second messenger signaling cascades, which control many cellular processes, including  
119 neuro-immune modulation, that may play a key role in the pathogenesis of AD<sup>24</sup>. Increases in SP are  
120 known to induce secretion of pro-inflammatory mediators, such as TNF- $\alpha$ , IFN- $\gamma$ , and IL-2<sup>25</sup>. SP signaling  
121 in the skin also upregulates the expression of nerve growth factor (NGF), which affects pruriception in  
122 the skin<sup>26</sup>. These factors may combine to neuronal hypersensitivity of sensory small fibers towards itch  
123 by reducing the threshold of cutaneous nerve fibers for pruritogens. A typical clinical sign for neuronal  
124 hypersensitivity is alloknesis (patients scratch and as a result worsen their itching). Preclinical models  
125 confirm that administration of NK-1 receptor antagonist decreased scratching behavior in mice<sup>27</sup>. This  
126 evidence suggests that inhibition of this signaling pathway via an NK-1 receptor antagonist may lead to

127 reduction of SP-induced pruritus in AD. Tradipitant (VLY-686), a novel NK-1 receptor antagonist, has the  
128 potential to reduce itch related to AD through inhibition of SP-mediated itch signaling.

129 A previous phase 2 study (Study 2102) was conducted at 28 centers in the US<sup>28</sup>. Study 2102  
130 demonstrated that eight weeks of tradipitant treatment improved worst itch and disease severity. These  
131 results led to the design of the phase 3 study, EPIONE, studying tradipitant treatment in 375 patients  
132 with chronic pruritus associated with AD. The results of EPIONE are presented here as an 8-week,  
133 placebo-controlled study to determine the efficacy and safety of twice-daily tradipitant administration in  
134 reduction of chronic pruritus in patients with AD.

135 **Methods**

136 **Study design**

137 EPIONE was a randomized, double-blind, placebo-controlled phase 3 study and was approved by human  
138 research ethics committees at all participating institutions. Participants provided written informed  
139 consent and were provided a copy of the signed consent form before any screening procedures  
140 occurred. The study was conducted across 74 sites in the United States, from July 09, 2018 to December  
141 27, 2019. Participants were randomly assigned to tradipitant (85 mg) or matched placebo, which was  
142 taken orally twice-daily (morning and evening) for 8 weeks. No participants (investigators, study staff,  
143 patients) knew the treatment assignment, and blinding was maintained throughout the study through  
144 database lock.

145  
146 This study had two phases: the screening phase and the evaluation phase. The screening phase  
147 consisted of an initial visit to evaluate eligibility, followed by a wash-out period lasting 14 to 45 days.  
148 Participants completed a daily diary throughout this washout period. Participants meeting all eligibility  
149 criteria were randomized at the baseline visit and were dispensed study medication. Participants were  
150 randomized (1:1) using an automated interactive web response system. Participants who did not meet  
151 eligibility criteria were considered screen failures. During the evaluation phase, patients returned to the  
152 clinic for four additional study visits where safety and efficacy assessments were performed.

153 **Participants**

154 Participants were men and women aged between 18 and 70 years, with chronic pruritus related to AD  
155 that was refractory to treatment by patient history, pruritus intensity rated by the Worst Itch Numerical  
156 Rating Scale (WI-NRS) diary average score of 7 or greater, and  $\geq 1\%$  body surface area of AD  
157 involvement.

158 **Assessments and Outcomes**

159 Itch was assessed by the patient by WI-NRS during the study visits. Responses were measured by an 11-  
160 point numeric scale with 0 being “No Itching” and 10 being “Worst Itch Imaginable”. Disease severity  
161 was assessed by the investigators utilizing the SCORing Atopic Dermatitis (SCORAD) index<sup>29</sup>, the Eczema  
162 Area and Severity Index (EASI)<sup>30</sup>, and the validated Investigator Global Assessment for Atopic Dermatitis  
163 (vIGA-AD<sup>TM</sup>). Sleep disturbance was measured by daily diary 11-point numerical rating scale (NRS) with 0  
164 being “No Sleep Disruption” and 10 being “Very Severe Sleep Disruption”, 100 mm SCORAD visual  
165 analogue scale (VAS), and the Patient-Oriented Eczema Measure (POEM)<sup>31</sup>.

166 The primary objective was to evaluate the efficacy of tradipitant in reducing worst itch as measured by  
167 WI-NRS at Week 8. Secondary objectives included evaluating the response rate of  $\geq 4$  points on WI-NRS,  
168 improvement in disease severity by vIGA-AD, SCORAD, and EASI, improvement in sleep, and to explore  
169 the safety and efficacy of multiple oral doses of tradipitant.

170 Safety assessments included the regular monitoring and recording of all adverse events (AEs) and  
171 serious adverse events (SAEs); monitoring of hematology, serum chemistry, and urinalysis values, vital  
172 signs, body measurements, and suicidal ideation and behavior; and the performance of physical  
173 examinations and ECGs.

174

175 **Statistical analyses**

176 375 participants were enrolled in EPIONE. This sample size was determined based on previous historical  
177 data. Statistical analyses were performed using two-sided tests; significance was considered at  $P \leq 0.05$ .

178 The intent-to-treat (ITT) population was defined as all individuals randomized into the study who  
179 received a dose of study drug and completed at least one post-baseline efficacy measurement while on

180 study medication. The primary analysis for efficacy used mixed model repeated measures (MMRM)  
181 analysis. The responder analysis was based on a two-sided Fisher's Exact Test. All analyses and  
182 tabulations were performed using SAS®.

183 **Role of funding source**

184 The sponsor designed the study. All authors, including those representing the sponsor, contributed to  
185 data interpretation and writing of the report. All authors had final responsibility for the decision to  
186 submit for publication.

187 **Results**

188 EPIONE screened 1015 individuals and enrolled 375 patients meeting the inclusion criteria, with 286  
189 patients completing the study (**Figure 1**). The ITT population consisted of 341 patients (VLY-686 = 171,  
190 PBO = 170). There were no significant differences across treatment groups in baseline demographics and  
191 disease severity (**Table I**).

192 Although there was a numerical benefit in the tradipitant group over placebo, EPIONE did not meet the  
193 primary endpoint of reduction in pruritus across the overall study population. Specifically, at Week 8,  
194 tradipitant and placebo patients both demonstrated significant and meaningful improvement in pruritus  
195 from baseline, but while the tradipitant magnitude of improvement was greater than that of placebo,  
196 the difference between treatment groups was not statistically significant (**Table II**, -0.2 (-0.8 to 0.4),  $P =$   
197 0.567). A significant interaction was observed between baseline disease severity (as defined by vIGA-AD  
198 score 0-4) and treatment ( $P < 0.001$ ). This suggests that study participants with different baseline  
199 disease severities experienced different treatment outcomes. When adjusting for baseline disease  
200 severity and treatment in the ITT population, a significantly larger improvement in WI-NRS was seen in  
201 tradipitant-treated patients at Week 8 (**Table II**, -1.1 (-2.0 to -0.2),  $P = 0.022$ ).

202 A subgroup analysis showed that patients with mild disease severity (baseline vIGA-AD 1 or 2,  $n = 79$ ;  
203 VLY-686 = 40, PBO = 39) had a significantly greater itch improvement when comparing tradipitant to  
204 placebo (-1.6 (-2.9 to -0.3),  $P = 0.015$ ). Similar effects were seen throughout the treatment period at all  
205 post-randomization visits (Weeks 2, 4, 6, and 8) (**Figure 2 and 3a**). This treatment response in mild AD  
206 was confirmed by patient-reported daily diary worst itch improvement (**Table II**, -2.09 (-3.31 to -0.87),  $P =$   
207 0.001). Importantly, significant improvement in pruritus was observed after one day of tradipitant  
208 treatment (**Figure 3b**, -0.61 (-1.21 to -0.01),  $P = 0.0457$ ). Two to four point improvement on the WI-NRS  
209 scale is considered clinically meaningful<sup>32</sup>. After eight weeks of treatment, 72.5% of tradipitant-treated

210 patients achieved a reduction of 4 points or greater compared to 33.3% of placebo-treated patients  
211 (**Figure 3e**, 39.2 (18.9 to 59.4),  $P < 0.001$ ).

212 Consistent with improvement on WI-NRS, mild AD patients also showed statistically significant  
213 improvement on the subjective SCORAD subscale relative to placebo (**Table II**, -3.02 (-5.37 to -0.66),  $P =$   
214 0.013). However, overall disease severity improvement was not seen in mild AD patients as measured by  
215 SCORAD (-4.09 (-11.07 to 2.89),  $P = 0.247$ ) and EASI (-0.57 (-1.70 to 0.57),  $P = 0.321$ ). In a responder  
216 analysis, 55% of tradipitant-treated patients saw their SCORAD reduced by at least half throughout the 8  
217 weeks of treatment compared to 30.8% for those on placebo (**Figure 3e**, 24.2 (3.1 to 45.4),  $P = 0.041$ ).

218 In addition to robust improvement in itch, improvement in nighttime sleep was also observed in mild  
219 AD. Mild AD patients experienced significant improvement in sleep as measured by the SCORAD VAS for  
220 average sleep disturbance over the last 72 hours after 8 weeks of tradipitant treatment (**Table II**, -1.46 (-  
221 2.60 to -0.32)  $P = 0.013$ ). This improvement was confirmed by daily diary Sleep NRS (-1.14 (-2.3, 0.02),  $P$   
222 = 0.053) and POEM sleep disturbance (-0.7 (-1.3 to -0.2),  $P = 0.009$ ). A similar pattern was observed in  
223 SCORAD throughout the study (**Figure 3c**, Week 2 [-1.37 (-2.14, -0.61),  $P < 0.001$ ] Week 4 [-2.01 (-3.04, -  
224 0.99)  $P < 0.001$ ]; Week 6 [-1.62 (-2.72, -0.53),  $P = 0.004$ ]). Statistically significant improvement in sleep  
225 was seen after two full days of tradipitant treatment (**Figure 3d**, -0.88 (-1.58, -0.18),  $P = 0.0147$ ).

226 The most frequent treatment emergent adverse events (TEAEs) were mild to moderate. There were no  
227 common TEAEs identified in the treatment arm as defined by  $> 5\%$  incidence. TEAEs with  $> 2\%$  incidence  
228 and twice that of placebo included diarrhea, fatigue, and worsening of AD. Severe TEAEs were reported  
229 in 5 patients, but were all determined to be unrelated to the study drug. No deaths were reported in the  
230 study.

231 **Discussion**

232 In EPIONE, daily treatment of tradipitant for 8 weeks did not meet the primary endpoint of reduction in  
233 pruritus across the overall study population of patients with chronic pruritus related to AD, which  
234 included mild (23%), moderate (64%), and severe (13%) AD. However, tradipitant treatment resulted in  
235 a clinically meaningful reduction in patient reported worst itch and sleep disturbance in the mild AD  
236 study population. Statistically significant improvement was seen after a single day of treatment for itch  
237 and two days of treatment for sleep. Mild AD represents over 60% of the total AD population in the US<sup>2</sup>,  
238 thus this study potentially addresses a highly unmet need of treating pruritus for a large portion of AD  
239 patients that suffer from significant pruritus and sleep disturbance despite their mild lesions.

240 It is possible that the immediate and robust improvements observed in the mild AD subgroup were seen  
241 not only because of different levels of cutaneous inflammation but also because of distinct AD  
242 endotypes that are currently being defined for AD based on age, race, inflammatory, and genetic  
243 profiles<sup>14,15</sup>. We can confirm this hypothesis as Smieszek et al. (2020) showed that EPIONE patients with  
244 baseline IGA of 1,2 (mild) versus 3,4 (moderate to severe) have different sets of causative factors and  
245 courses, including different clinical manifestations, molecular levels, and genetic associations. The  
246 concept of different endotypes in AD underlines the need for targeted therapeutics in different AD  
247 disease types<sup>14,15</sup>.

248 Additionally, it is known that AD skin is enriched with hypersensitive sensory nerves that secrete  
249 elevated levels of SP<sup>25</sup>. These elevated levels of SP signal transmission of itch from peripheral nerves  
250 through the dorsal root ganglion to the brain where itch is perceived<sup>8</sup>. However, there are plenty of  
251 other itch mediators in AD including NGF, IL-2, IL-4, IL-13, and IL-31<sup>8</sup>. It is possible that in mild AD  
252 neuronal hypersensitivity and neuronal factors such as SP are the predominant pruriceptive  
253 mechanisms, while in moderate to severe AD immune mechanisms including interleukin release

254 predominate and/or dilute the importance of SP signaling. As more pruritic factors propagate itch, the  
255 less efficacious a targeted therapy to reduce SP signaling may become. This may explain some of the  
256 effect observed in the overall study population in EPIONE.

257 Itch in AD is often worse at night<sup>33</sup>. Disturbed sleep has been reported in 33-81% of AD patients and is a  
258 major factor leading to impaired quality of life, and thus is a high unmet medical need<sup>34</sup>. After  
259 tradipitant treatment, improvement in sleep in mild AD patients was observed across three patient  
260 reported assessments, objective SCORAD VAS, daily diary, and POEM. Statistically significant  
261 improvement was seen after two days of treatment. Further study is needed to understand the minimal  
262 clinically important difference for these assessments to determine overall impact on quality of life.  
263 However, these results suggest that tradipitant can improve quality of life through the reduction of  
264 sleep disturbance.

265 Tradipitant may represent a new oral systemic option for mild AD patients based on the well-tolerated  
266 safety profile and immediate robust improvement in itch and sleep. Future studies are needed to  
267 confirm these efficacy results and refine treatment recommendations for AD patients who despite  
268 having mild lesions experience significant pruritus.

269 **Acknowledgements**

270 We thank the investigators, study staff, and study patients who participated in this study.

271 **References**

- 272 1. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from  
273 an international survey. *Allergy Eur J Allergy Clin Immunol*. 2018;(January):1-10.  
274 doi:10.1111/all.13401
- 275 2. Chiesa Fuxench ZC, Block J, Boguniewicz M, et al. Atopic Dermatitis in America Study: a cross-  
276 sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult  
277 population. 2018. doi:10.1016/j.jid.2018.08.028
- 278 3. Correale CE, Walker C, Murphy L, Craig TJ. Atopic dermatitis: a review of diagnosis and  
279 treatment. *AmFamPhysician*. 1999;60(0002-838X (Print)):1110-1191.
- 280 4. Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD):  
281 Insights from a phase 2b clinical trial of dupilumab in adults. *J Am Acad Dermatol*.  
282 2016;74(3):491-498. doi:10.1016/j.jaad.2015.10.043
- 283 5. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management  
284 of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad*  
285 *Dermatol*. 2014;70(2):338-351. doi:10.1016/J.JAAD.2013.10.010
- 286 6. Huet F, Faffa MS, Poizeau F, Merhand S, Misery L, Brenaut E. Characteristics of pruritus in  
287 relation to self-assessed severity of atopic dermatitis. *Acta Derm Venereol*. 2019;99(3):279-283.  
288 doi:10.2340/00015555-3053
- 289 7. Dawn A, Papoiu ADP, Chan YH, Rapp SR, Rasette N, Yosipovitch G. Itch characteristics in atopic  
290 dermatitis: results of a web-based questionnaire. *Br J Dermatol*. 2009;160(3):642-644.  
291 doi:10.1111/j.1365-2133.2008.08941.x
- 292 8. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of Chronic Pruritus in Atopic Dermatitis:  
293 Getting the Itch Out? *Clin Rev Allergy Immunol*. 2016;51(3):263-292. doi:10.1007/s12016-015-  
294 8488-5

- 295 9. Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease  
296 and disease severity with patient-reported disease burden in adults with atopic dermatitis. *JAMA*  
297 *Dermatology*. 2018;154(8):903-912. doi:10.1001/jamadermatol.2018.1572
- 298 10. Cabanillas B, Brehler A-C, Novak N. Atopic dermatitis phenotypes and the need for personalized  
299 medicine. *Curr Opin Allergy Clin Immunol*. 2017;17(4):309-315.  
300 doi:10.1097/ACI.0000000000000376
- 301 11. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. *Allergy*.  
302 2013;68(8):974-982. doi:10.1111/all.12184
- 303 12. Sandilands A, Sutherland C, Irvine AD, McLean WHI. Filaggrin in the frontline: role in skin barrier  
304 function and disease. *J Cell Sci*. 2009;122(Pt 9):1285-1294. doi:10.1242/jcs.033969
- 305 13. O'Regan GM, Sandilands A, McLean WHI, Irvine AD. Filaggrin in atopic dermatitis. *J Allergy Clin*  
306 *Immunol*. 2009;124(3 Suppl 2):R2-6. doi:10.1016/j.jaci.2009.07.013
- 307 14. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications  
308 for targeted therapeutics. *J Allergy Clin Immunol*. 2019;143(1):1-11.  
309 doi:10.1016/j.jaci.2018.10.032
- 310 15. Brown SJ, McLean WHI. Eczema genetics: Current state of knowledge and future goals. *J Invest*  
311 *Dermatol*. 2009;129(3):543-552. doi:10.1038/jid.2008.413
- 312 16. Yosipovitch G, Papoiu ADP. What causes itch in atopic dermatitis? *Curr Allergy Asthma Rep*.  
313 2008;8(4):306-311. doi:10.1007/s11882-008-0049-z
- 314 17. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper  
315 on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *J Eur Acad*  
316 *Dermatology Venereol*. 2016;30(5):729-747. doi:10.1111/jdv.13599
- 317 18. Wei W, Ghorayeb E, Andria ML, et al. 204 A real-world study evaluating adequacy of Existing  
318 Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST):

- 319 Baseline treatment patterns and unmet needs assessment. *J Invest Dermatol.* 2017;137(5):S35.  
320 doi:10.1016/j.jid.2017.02.219
- 321 19. Schmitt J, Csötönyi F, Bauer A, Meurer M. Determinants of treatment goals and satisfaction of  
322 patients with atopic eczema. *JDDG.* 2008;6(6):458-465. doi:10.1111/j.1610-0387.2007.06609.x
- 323 20. Teresiak-Mikołajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic markers of the  
324 inflammatory process in atopic dermatitis: Relation to the severity and pruritus. *Postep*  
325 *Dermatologii i Alergol.* 2013;30(5):286-292. doi:10.5114/pdia.2013.38357
- 326 21. Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The Genetics of Chronic Itch: Gene Expression  
327 in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. *J Invest Dermatol.*  
328 2018;138(6):1311-1317. doi:10.1016/j.jid.2017.12.029
- 329 22. Almeida TA, Rojo J, Nieto PM, et al. Tachykinins and tachykinin receptors: structure and activity  
330 relationships. *CurrMedChem.* 2004;11(0929-8673 (Print)):2045-2081.
- 331 23. Johnson MB, Young AD, Marriott I. The Therapeutic Potential of Targeting Substance P/NK-1R  
332 Interactions in Inflammatory CNS Disorders. *Front Cell Neurosci.* 2017;10(January):1-14.  
333 doi:10.3389/fncel.2016.00296
- 334 24. Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system in  
335 reference to selected infections and inflammation. *Ann N Y Acad Sci.* 2011;1217:83-95.  
336 doi:10.1111/j.1749-6632.2010.05826.x
- 337 25. Zhang Z, Zheng W, Xie H, et al. Up-regulated expression of substance P in CD8+ T cells and NK1R  
338 on monocytes of atopic dermatitis. *J Transl Med.* 2017;15(1):93. doi:10.1186/s12967-017-1196-6
- 339 26. Wei T, Guo T-Z, Li W-W, Hou S, Kingery WS, Clark JD. Keratinocyte expression of inflammatory  
340 mediators plays a crucial role in substance P-induced acute and chronic pain. *J*  
341 *Neuroinflammation.* 2012;9:181. doi:10.1186/1742-2094-9-181
- 342 27. Ohmura T, Hayashi T, Satoh Y, Konomi A, Jung B, Satoh H. Involvement of substance P in

- 343 scratching behaviour in an atopic dermatitis model. *Eur J Pharmacol.* 2004;491(2-3):191-194.  
344 doi:10.1016/j.ejphar.2004.03.047
- 345 28. Heitman A, Xiao C, Cho Y, Polymeropoulos C, Birznieks G, Polymeropoulos MH. Tradipitant  
346 improves worst itch and disease severity in patients with chronic pruritus related to atopic  
347 dermatitis. *J Am Acad Dermatol.* 2018;79(3):AB300. doi:10.1016/j.jaad.2018.05.1184
- 348 29. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on  
349 interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-  
350 item severity score. *Br J Dermatol.* 2007;157(4):645-648. doi:10.1111/j.1365-2133.2007.08112.x
- 351 30. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity  
352 index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. *Exp Dermatol.*  
353 2001;10(0906-6705 (Print)):11-18.
- 354 31. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and  
355 initial validation of a new tool for measuring atopic eczema severity from the patients'  
356 perspective. *Arch Dermatol.* 2004;140(12):1513-1519. doi:10.1001/archderm.140.12.1513
- 357 32. Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric  
358 validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. *Br*  
359 *J Dermatol.* 2019;181(4):761-769. doi:10.1111/bjd.17744
- 360 33. Chang Y Sen, Chiang BL. Mechanism of sleep disturbance in children with atopic dermatitis and  
361 the role of the circadian rhythm and melatonin. *Int J Mol Sci.* 2016;17(4).  
362 doi:10.3390/ijms17040462
- 363 34. Jeon C, Yan D, Nakamura M, et al. Frequency and Management of Sleep Disturbance in Adults  
364 with Atopic Dermatitis: A Systematic Review. *Dermatol Ther (Heidelb).* 2017;7(3):349-364.  
365 doi:10.1007/s13555-017-0192-3  
366

367 **Figure Legend**

368 Figure 1. EPIONE Profile and Design.

369

370 Figure 2. Worst Itch NRS Change by Week. Mild atopic dermatitis patients have greater improvement in  
371 worst itch after tradipitant-treatment. Forest plots of the analysis of ITT and IGA 1,2 WI-NRS change by  
372 week. Plotted as LS Mean Difference and 95% CI after tradipitant or placebo treatment.

373

374 Figure 3. Tradipitant-treatment Improves Itch and Sleep in Mild Atopic Dermatitis. A. Tradipitant-  
375 treatment improved worst itch in mild AD. B. Improvement in itch was observed after one full day of  
376 tradipitant treatment. C. Tradipitant-treatment improved sleep disturbance in mild AD. D. Improvement  
377 in sleep was seen after two full days of tradipitant treatment. E. A greater proportion of mild AD patients  
378 achieved success of four points or greater on WI-NRS and at least a 50% improvement on SCORAD. A-D.  
379 *P* values are from MMRM analysis. E. *P* values are from Fisher's exact test. \**P* < 0.05

380 **Table Legend**

381 Table I. Baseline Demographic and Clinical Characteristics. Data are in mean (SD) or number (%).

382 BMI=body mass index, NRS=numerical rating scale, SCORAD=SCORing Atopic Dermatitis index,

383 EASI=Eczema Area and Severity Index, vIGA-AD=validated Investigator Global Assessment for Atopic

384 Dermatitis, BSA=body surface area ^VLY-686 n = 166, PBO n = 166, Overall N = 322

385

386 Table II. Efficacy Measures at Week 8. <sup>1</sup>P values are from MMRM analysis. <sup>^</sup>ITT n = 341, VLY-686 n = 171,

387 PBO n = 170. <sup>#</sup>IGA ≤ 2 n = 79, VLY-686 n = 40, PBO n = 39



388 Table 1. Baseline Demographic and Clinical Characteristics.

	<b>Placebo n = 170</b>	<b>Tradipitant n = 171</b>	<b>Overall N = 341</b>
Age, mean (SD)	41.9 (15.5)	41.4 (15.2)	41.6 (15.3)
Male, n (%)	60 (35.3)	58 (33.9)	118 (34.6)
Ethnic origin, n (%)			
<i>White</i>	115 (67.6)	113 (66.1)	228 (66.9)
<i>Black</i>	38 (22.4)	45 (26.3)	83 (24.3)
<i>Asian</i>	10 (5.9)	9 (5.3)	19 (5.6)
<i>Other</i>	7 (4.1)	4 (2.3)	11 (3.2)
BMI (kg/m <sup>2</sup> )	28.4 (5.0)	28.0 (5.3)	28.2 (5.2)
Worst Itch-NRS	8.1 (1.3)	8.2 (1.2)	8.2 (1.3)
BSA	14.38 (17.2)	14.05 (17.4)	14.21 (17.2)
SCORAD	51.31 (14.2)	49.7 (14.7)	50.5 (14.5)
EASI	10.62 (10.0)	10.47 (10.9)	10.54 (10.4)
vIGA-AD, n (%)			
<i>Almost Clear (1)</i>	0 (0)	2 (1.2)	2 (0.6)
<i>Mild (2)</i>	39 (22.9)	38 (22.2)	77 (22.6)
<i>Moderate (3)</i>	105 (61.8)	113 (66.1)	218 (63.9)
<i>Severe (4)</i>	26 (15.3)	18 (10.5)	44 (12.9)
Eosinophil Count (10 <sup>9</sup> /L)	0.24 (0.2)	0.27 (0.3)	0.25 (0.2)
FLG LOF <sup>^</sup>	28 (16.9)	23 (13.9)	51 (15.4)


390 Table 2. Efficacy Measures at Week 8.

<b>Endpoints<sup>1</sup></b>	<b>Tradipitant</b>	<b>Placebo</b>	<b>Difference</b>	<b>P value</b>
<b>Itch Outcomes</b>				
WI-NRS <sup>^</sup>	-3.61	-3.43	0.18	0.5667
WI-NRS Adjusting for IGA Severity <sup>^</sup>	-4.36	-3.28	1.08	0.0217
WI-NRS <sup>#</sup>	-4.74	-3.14	1.60	0.0152
Diary WI-NRS <sup>#</sup>	-4.23	-2.14	2.09	0.0010
<b>Disease Outcomes</b>				
SCORAD Total <sup>#</sup>	-18.92	-14.83	-4.09	0.2466
Objective SCORAD <sup>#</sup>	-9.94	-9.22	-0.72	0.7955
Subjective SCORAD <sup>#</sup>	-8.81	-5.79	-3.02	0.0127
EASI Total <sup>#</sup>	-2.19	-1.62	-0.57	0.3210
<b>Sleep Outcomes</b>				
SCORAD Sleep Disturbance <sup>#</sup>	-4.09	-2.63	-1.46	0.0131
Diary Sleep Disturbance <sup>#</sup>	-3.12	-1.98	-1.14	0.0534
POEM Sleep Disturbance <sup>#</sup>	-1.66	-0.9	-0.72	0.0086

391



		OR (95% CI)
IGA 1,2 WI-NRS	Week 2	1.61 (0.77, 2.45)
	Week 4	1.92 (0.86, 2.97)
	Week 6	1.86 (0.68, 3.03)
	Week 8	1.60 (0.32, 2.88)
ITT WI-NRS	Week 2	0.23 (-0.22, 0.69)
	Week 4	0.39 (-0.16, 0.94)
	Week 6	0.11 (-0.48, 0.71)
	Week 8	0.18 (-0.44, 0.80)



● Placebo  
■ Tradipitant

